Peptide-Based Ophthalmic Solution
Expected to Control Inflammation and Improve Keratoconjunctivitis

Huons has entered the next phase of clinical trials for the development of a new mechanism dry eye disease drug.


On March 12, Huons announced that it had received approval from the Ministry of Food and Drug Safety on the previous day (March 11) for the Phase 2 clinical trial plan (IND) of 'HUC1-394', a new drug candidate for the treatment of dry eye disease.

Huons Receives IND Approval for Phase 2 Clinical Trial of Dry Eye Disease Drug 'HUC1-394' View original image

HUC1-394 is a peptide-based ophthalmic solution introduced by Huons from Novacell Technology Co., Ltd.


This substance selectively binds to and activates the formyl peptide receptor 2 (FPR2), a receptor involved in the resolution process of inflammation in the body. By not only suppressing inflammation but also properly terminating the inflammatory response and restoring damaged tissue, it is expected to fundamentally improve dry eye disease by ameliorating keratoconjunctivitis (inflammation of the cornea and conjunctiva).


Last year, Huons demonstrated the safety and tolerability of HUC1-394 through a Phase 1 clinical trial involving 60 healthy adults. At that time, no serious adverse events (SAEs) occurred as a result of single and repeated administration, providing sufficient grounds for subsequent clinical trials.


With this Phase 2 clinical trial approval, Huons will conduct the study at major medical institutions, including Severance Hospital of Yonsei University College of Medicine, administering the trial to 150 patients with dry eye disease. The trial will be conducted using a multi-center, randomized, double-masked (RCT) design to confirm the safety and efficacy of HUC1-394 and to explore the optimal dosage regimen.

Huons expects that HUC1-394 will effectively control inflammation, the main cause of dry eye disease, while also minimizing the potential for side effects.



Kyungmi Park, Executive Vice President of R&D at Huons, stated, "Through the analysis of the Phase 1 clinical trial results for HUC1-394, we have confirmed the validity of proceeding with subsequent clinical trials." She added, "Starting with this IND approval, we will do our best to carry out Phase 2 clinical trials without delay, so that we can provide a new treatment option for patients suffering from dry eye disease."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing